GPT and COVID-19: Gastrointestinal presentation was observed in patients at risk of developing severe COVID-19 (i.e., with higher BMI, high incidence of hypertension, elevated SGPT levels and low lymphocyte count) with a significant mortality of 18% [7,8,9,10,11,26].